The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison
Open accessAbstract
Summary Background The burden of Plasmodium vivax infections has been underappreciated, especially in southeast Asia where chloroquine resistant strains have emerged. Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by multidrug-resistant P falciparum and P vivax. Methods 774 patients in southern Papua, Indonesia, with slide-confirmed malaria were randomly assigned to receive either artemether-lumefantrine or dihydroartemisinin-piperaquine and followed up for at least 42 days. The primary endpoint was the overall cumulative risk of parasitological failure at day 42 with a modified intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, trial number 00157833. Findings Of the 754 evaluable patients enrolled, 466 had infections with P falciparum, 175 with P vivax, and 113 with a mixture of both species. The overall risk of failure at day 42 was 43% (95% CI 38–48) for artemether-lumefantrine and 19% (14–23) for dihydroartemisinin-piperaquine (hazard ratio=3·0, 95% CI 2·2–4·1, p<0·0001). After correcting for reinfections, the risk of recrudescence of P falciparum was 4·4% (2·6–6·2) with no difference between regimens. Recurrence of vivax occurred in 38% (33–44) of patients given artemether-lumefantrine compared with 10% (6·9–14·0) given dihydroartemisinin-piperaquine (p<0·0001). At the end of the study, patients receiving dihydroartemisinin-piperaquine were 2·0 times (1·2–3·6) less likely to be anaemic and 6·6 times (2·8–16) less likely to carry vivax gametocytes than were those given artemether-lumefantrine. Interpretation Both dihydroartemisinin-piperaquine and artemether-lumefantrine were safe and effective for the treatment of multidrug-resistant uncomplicated malaria. However, dihydroartemisinin-piperaquine provided greater post-treatment prophylaxis than did artemether-lumefantrine, reducing P falciparum reinfections and P vivax recurrences, the clinical public-health importance of which should not be ignored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Satpathy, S. K., Mohanty, N., Nanda, P., & Samal, G. (2004) · The Indian Journal of Pediatrics · doi:10.1007/bf02723094 · Cited by 1,130
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster.
(2000) · PubMed · Cited by 920
PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE?
Rieckmann, K. H., Davis, D. R., & Hutton, D. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91792-3 · Cited by 501
Bloland, P. B., Ringwald, P., & Snow, R. W. (2003) · Cited by 499
Antimalarial drug resistance and combination chemotherapy
White, N. (1999) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1999.0426 · Cited by 477
Effects of artemisinin derivatives on malaria transmissibility
Price, R. N., Nosten, F., Luxemburger, C., ter Kuile, F. O., Paiphun, L., Price, R. N., Luxemburger, C., Chongsuphajaisiddhi, T., White, N. J., Price, R. N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91488-9 · Cited by 462
Self-citationPharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria
Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S., & White, N. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.697-704.2000 · Cited by 354
Resistance to Chloroquine by Plasmodium vivax in Irian Jaya, Indonesia
Baird, J. K., Basri, H., Purnomo, Bangs, M. J., Subianto, B., Patchen, L. C., & Hoffman, S. L. (1991) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1991.44.547 · Cited by 232
Piola, P., Fogg, C., Bajunirwe, F., Biraro, S., Grandesso, F., Ruzagira, E., Babigumira, J., Kigozi, I., Kiguli, J., Kyomuhendo, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66416-1 · Cited by 211
The assessment of antimalarial drug efficacy
White, N. J. (2002) · Trends in Parasitology · doi:10.1016/s1471-4922(02)02373-5 · Cited by 207
Cited by
Vivax Malaria: Neglected and Not Benign
Price, R. N., Tjitra, E., Guerra, C. A., Yeung, S., White, N. J., & Anstey, N. M. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.79 · Cited by 838
Self-citationBousema, T., & Drakeley, C. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-10 · Cited by 746
Determinants of relapse periodicity in Plasmodium vivax malaria
White, N. J. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-297 · Cited by 679
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite
Mueller, I., Galinski, M. R., Baird, J. K., Carlton, J. M., Kochar, D. K., Alonso, P. L., & del Portillo, H. A. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70177-x · Cited by 661
Tjitra, E., Anstey, N. M., Sugiarto, P., Warikar, N., Kenangalem, E., Karyana, M., Lampah, D. A., & Price, R. N. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050128 · Cited by 611
Self-citation
Metadata
- Authors
- Ratcliff, A., Siswantoro, H., Kenangalem, E., Maristela, R., Wuwung, R., Laihad, F., Ebsworth, E., Anstey, N., Tjitra, E., & Price, R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 369
- Issue
- 9563
- Pages
- 757-765
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2166357496
- Cited by
- 271
- References
- 30
- FWCI
- 32.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. https://app.cochat.ai/papers/10.1016/s0140-6736(07)60160-3
- The paper
- Ratcliff, A., Siswantoro, H., Kenangalem, E., Maristela, R., Wuwung, R., Laihad, F., Ebsworth, E., Anstey, N., Tjitra, E., & Price, R. (2007). Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. The Lancet. https://doi.org/10.1016/s0140-6736(07)60160-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.